Friday, July 10, 2026

pharma · Advanced Solid Tumor · Chronic Lymphocytic Leukemia

BEONE MEDICINES AUS

BEONE MEDICINES AUS is a pharma organization headquartered in Cambridge, USA. Primary therapeutic focus areas include Advanced Solid Tumor, Chronic Lymphocytic Leukemia, Solid Tumor, Adult, Mantle Cell Lymphoma, Previous

Cambridge, USA HQ
2010 Founded
3,177 Employees
TGA registrant Type
Company details
Clinical program

BGB-11417-203

Phase 2 · small molecule · previously untreated WM, Relapsed/Refractory Waldenström’s Macroglobulinemia

BGB-11417-203 for previously untreated WM, Relapsed/Refractory Waldenström’s Macroglobulinemia is a Phase 2 program (small_molecule) at BEONE MEDICINES AUS PTY LTD with 1 ClinicalTrials.gov record(s).

Internal code BGB-11417-203

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
BEONE MEDICINES AUS PTY LTD
Phase
Phase 2
Modality
small_molecule
Indication
previously untreated WM, Relapsed/Refractory Waldenström’s Macroglobulinemia
Status
active
Trials
1